GH Research PLC (GHRS NASDAQ) stock market data APIs
$21.0228
0.82(3.9%)
as of May 7, 2026
Try our APIs with
free plan!
GH Research PLC Financial Data Overview
Price chart is built with
Anychart
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Prev. Close
21.0228
Open
21.8428
High
22.5905
Low
20.5282
52 wk Range
9.4557-24.66
Market Cap
1 538 M
Shares Outstanding
68 557 K
EPS
0
Beta
1.279
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with GH Research PLC (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get GH Research PLC data using free add-ons & libraries
Get GH Research PLC Fundamental Data
GH Research PLC Fundamental data includes:
- Net Revenue:
- EBITDA: -60 599 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-05-07
- EPS/Forecast: -0.346
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
GH Research PLC News
New
FDA Fast-Tracks Review of Some Psychedelic Drugs. This Stock Is Set to Benefit.
Compass Pathways, the developer of synthetic psilocybin, announced it had received a government voucher. Continue Reading
Jefferies analyst says Trump's executive order on psychedelics is an 'official stamp of validation' for investors
Psychedelic drugmakers just got a jolt that Wall Street couldn't ignore. After President Donald Trump signed an executive order (1) aimed at fast-tracking research and access to psychedelic therapies ...
‘Can I have some, please?’: Trump jokes as he signs psychedelics order after Joe Rogan push. These stocks soar
Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below. Psychedelics — once largely confined to the fringes of medicine and culture — are now drawing at...
How Trump Sent Psychedelics-Tied Compass Pathways And Others Flying
Compass Pathways stock surged Monday after President Donald Trump signed an executive order tied to psychedelic drugs. Continue Reading
Get GH Research PLC fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
